The review summarizes and analyzes the clinical studies of five currently used drugs targeting PD-1/PD-L1 immune checkpoints approved by FDA, EMA, and NMPA in advanced NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.